Lung Cancer
Volume 68, Issue 2 , Pages 305-307 , May 2010

Exhaled ERCC-1 and ERCC-2 microsatellite alterations in NSCLC patients

  • Giovanna E. Carpagnano

      Affiliations

    • Institute of Respiratory Disease, Department of Medical and Occupational Sciences, University of Foggia, Italy
    • Corresponding Author InformationCorresponding author at: Institute of Respiratory Disease, Department of Medical and Occupational Sciences, University of Foggia, Ospedale D’Avanzo, Via degli Aviatori 1, 71100 Foggia, Italy. Tel.: +39 0881 733143; fax: +39 0881 733040.
    • ,
  • Grazia P. Palladino

      Affiliations

    • Institute of Respiratory Disease, Department of Medical and Occupational Sciences, University of Foggia, Italy
    • ,
  • C. Gramiccioni

      Affiliations

    • Institute of Respiratory Disease, Department of Medical and Occupational Sciences, University of Foggia, Italy
    • ,
  • Maria P. Foschino Barbaro

      Affiliations

    • Institute of Respiratory Disease, Department of Medical and Occupational Sciences, University of Foggia, Italy
    • ,
  • D. Martinelli

      Affiliations

    • Department of Medical Sciences, Section of Hygiene, University of Foggia, Apulia Regional Epidemiological Observatory, Italy

Received 29 October 2009

References 

  1. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, et al. DNA repair gene polymorphisms predict favourable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer. 2009;10(2):118–123
  2. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non small cell lung cancer. Chest. 2005;127(3):978–983
  3. Felip E, Rosell R. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. Expert Rev Mol Diagn. 2007;7(3):261–268
  4. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8:2286–2291
  5. Bicher A, Ault K, Kimmelman A, Gershenson D, Reed E, Liang B. Loss of heterozygosity in human ovarian cancer on chromosome 19q. Gynecol Oncol. 1997;66:36–40
  6. Bartolucci R, Wei J, Sanchez JJ, Perez-Roca L, Chaib I, Puma F, et al. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer. 2009;10(1):47–52
  7. Carpagnano GE, Foschino-Barbaro MP, Mulé G, Resta O, Tommasi S, Mangia A, et al. 3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer. Am J Respir Crit Care Med. 2005;172(6):738–744
  8. Carpagnano GE, Foschino-Barbaro MP, Spanevello A, Resta O, Carpagnano F, Mulé G, et al. 3p microsatellite signature in exhaled breath condensate and tumor tissue of patients with lung cancer. Am J Respir Crit Care Med. 2008;177(3):337–341
  9. Carpagnano GE, Spanevello A, Carpagnano F, Palladino GP, Prato R, Martinelli D, et al. Prognostic value of exhaled microsattellite alterations at 3p in NSCLC patients. Lung cancer. 2009;64(3):334–340

PII: S0169-5002(10)00063-2

doi: 10.1016/j.lungcan.2010.01.020

Lung Cancer
Volume 68, Issue 2 , Pages 305-307 , May 2010

Article Tools

* Image Usage & Resolution